> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts Outlook Therapeutics' Resubmitted BLA for Lytenava
- URL: https://www.fdaweb.com/fda-accepts-outlook-therapeutics-resubmitted-bla-for-lytenava/
- Published: 2026-06-17T12:00:00.000Z
- Updated: 2026-09-14T13:41:20.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5161328

FDA has accepted for review a BLA resubmission from Outlook Therapeutics seeking approval of ONS-5010/Lytenava (bevacizumab-vikg) for treating neovascular age-related macular degeneration, commonly known as wet AMD. The filing focuses on the review of product labeling and represents what the company described as the final step toward a potential approval. The Class 1 submission has been given a user fee review action target date of 7/29.

The resubmission comes on the heels of last month’s appeal win by Outlook following a Formal Dispute Resolution process with the agency’s Office of New Drugs ([see earlier story](https://www.fdaweb.com/outlook-wins-fda-appeal-after-3-complete-responses/)). The dispute stemmed from a BLA complete response letter (CRL) issued by FDA 12/2025.

The company has been rejected three times by FDA reviewers. An 8/2025 CRL cited insufficient evidence of effectiveness. The agency then said it could not approve the application in its current form because the pivotal NORSE EIGHT trial failed to meet its primary efficacy endpoint, according to the company. In 8/2023, FDA issued the original BLA a complete response letter that cited several chemistry, manufacturing and control issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence, according to the company.

Outlook says FDA has now concluded that “substantial evidence of effectiveness” had been established for Lytenava based on results from the company’s NORSE TWO clinical trial, together with confirmatory evidence from the NORSE EIGHT study and additional mechanistic and pharmacodynamic data.

If approved, Lytenava would become the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases supported by an FDA-approved manufacturing process and labeling, the company said. Bevacizumab, widely known in oncology under Roche’s Avastin brand, has long been used off-label by ophthalmologists to treat retinal diseases including wet AMD because of its lower cost relative to other anti-VEGF therapies. Outlook has been seeking approval for a specifically formulated ophthalmic version manufactured for intravitreal use.